|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SYT5 |
Gene summary for SYT5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SYT5 | Gene ID | 6861 |
| Gene name | synaptotagmin 5 | |
| Gene Alias | SYT5 | |
| Cytomap | 19q13.42 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | O00445 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6861 | SYT5 | P5T-E | Human | Esophagus | ESCC | 4.44e-08 | 1.53e-01 | 0.1327 |
| 6861 | SYT5 | P17T-E | Human | Esophagus | ESCC | 1.45e-12 | 5.22e-01 | 0.1278 |
| 6861 | SYT5 | P26T-E | Human | Esophagus | ESCC | 1.00e-24 | 5.02e-01 | 0.1276 |
| 6861 | SYT5 | P28T-E | Human | Esophagus | ESCC | 4.44e-08 | 1.94e-01 | 0.1149 |
| 6861 | SYT5 | P37T-E | Human | Esophagus | ESCC | 2.05e-28 | 6.74e-01 | 0.1371 |
| 6861 | SYT5 | P49T-E | Human | Esophagus | ESCC | 7.48e-03 | 4.05e-01 | 0.1768 |
| 6861 | SYT5 | P57T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.57e-01 | 0.0926 |
| 6861 | SYT5 | P80T-E | Human | Esophagus | ESCC | 1.26e-02 | 1.64e-01 | 0.155 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
| GO:007124117 | Esophagus | ESCC | cellular response to inorganic substance | 125/8552 | 226/18723 | 2.17e-03 | 9.67e-03 | 125 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SYT5 | SNV | Missense_Mutation | c.70N>T | p.His24Tyr | p.H24Y | O00445 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-A2-A0CV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| SYT5 | SNV | Missense_Mutation | c.388N>G | p.Leu130Val | p.L130V | O00445 | protein_coding | tolerated(0.31) | benign(0.104) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SYT5 | SNV | Missense_Mutation | c.503N>T | p.Thr168Met | p.T168M | O00445 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-D8-A1X8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimicin+cyclophosphamide | SD | |
| SYT5 | insertion | Frame_Shift_Ins | novel | c.947_948insCC | p.Asp317LeufsTer11 | p.D317Lfs*11 | O00445 | protein_coding | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| SYT5 | insertion | Nonsense_Mutation | novel | c.946_947insAAGCAGTACCAGATGCTCCACCCTAAGCAGGATCAGTAT | p.Pro315_Cys316insTer | p.P315_C316ins* | O00445 | protein_coding | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| SYT5 | deletion | Frame_Shift_Del | novel | c.625delN | p.Glu209ArgfsTer6 | p.E209Rfs*6 | O00445 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SYT5 | SNV | Missense_Mutation | novel | c.445N>T | p.Arg149Trp | p.R149W | O00445 | protein_coding | deleterious(0) | possibly_damaging(0.773) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SYT5 | SNV | Missense_Mutation | c.531N>G | p.Phe177Leu | p.F177L | O00445 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A6-6652-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Targeted Molecular therapy | cetuximab | SD | |
| SYT5 | SNV | Missense_Mutation | c.461N>T | p.Pro154Leu | p.P154L | O00445 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SYT5 | SNV | Missense_Mutation | c.793A>C | p.Asn265His | p.N265H | O00445 | protein_coding | deleterious(0.03) | probably_damaging(0.961) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |